Tag: Brentuximab Vedotin
Polatuzumab Vedotin in the Treatment of Patients with Previously Untreated Diffuse...
Diffuse large B-cell lymphoma (DLBCL), the most common type of an aggressive form of non-Hodgkin lymphoma (NHL) in the United States and worldwide, is...
ASH 2020: ECHELON-1 and ECHELON-2 and other Results with Brentuximab Vedotin
Presentations discussing brentuximab vedotin (Adcetris®; Seagen/Takeda) presented during the 62nd American Society of Hematology (ASH) Annual, Meeting, and Exposition, held virtually from December 5...
Seagen Presents Broad Portfolio of Innovative Immuno-Oncology Data – Featuring Sugar-Engineered...
During the upcoming 35th annual meeting of the Society for Immunotherapy of Cancer’s (SITC) being held November 9-14, 2020, Seagen (previously known as Seattle...
ASH 2019: Brentuximab Vedotin + Nivolumab in Frontline and R/R Hodgkin...
Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) and nivolumab (Opdivo®; Bristol‑Myers Squibb) in frontline Hodgkin lymphoma...
What to Expect at ASH 2019: Seattle Genetics
With the 61st annual meeting of the American Society of Hematology about to begin, here are some of the presentations to look for.
This year...
Health Canada Approves Brentuximab Vedotin + Chemotherapy in Frontline CD30-Expressing Peripheral...
Health Canada has approved the supplemental New Drug Submission that expands the use of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) in combination with CHP (cyclophosphamide,...
Phase III Clinical Trials of Brentuximab Vedotin Continue to Demonstrate Superior...
Additional, updated, analyses of results from ECHELON-1 and ECHELON-2, the frontline phase III trials of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda), an antibody-drug conjugate or...
ASH 2018 Highlights Progress in Ongoing Development of Brentuximab Vedotin
As the premier hematology event in malignant and non-malignant hematology, the annual meeting of the American Society of Hematology (ASH), held this year from...
Supplemental Biologics License Application for Brentuximab Vedotin in Frontline Treatment of...
Seattle Genetics has submitted a supplemental Biologics License Application (BLA) for brentuximab vedotin (Adcetris®) to the U.S. Food and Drug Administration (FDA).
The submission is...
Four Ways to Show Nonobviousness of ADC Inventions
As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.
